Vacasa, Inc. (VCSA)
Chart Events
Performance Outlook
| Previous Close | 3.0900 |
| Open | 3.1200 |
| Bid | 3.1000 x 1100 |
| Ask | 3.1100 x 2200 |
| Day's Range | 3.0650 - 3.2000 |
| 52 Week Range | 2.4200 - 11.0000 |
| Volume | |
| Avg. Volume | 1,206,204 |
| Market Cap | 1.333B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1820 |
| Earnings Date | May 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.40 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VCSA
Related Research
- Vacasa, Inc.Daily – Vickers Top Buyers & Sellers for 03/25/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat3 months agoArgus Research
- Business Wire
What a Guest Wants: Vacasa Releases 2022 Vacation Rental Search Report
PORTLAND, Ore., June 28, 2022--Vacasa (Nasdaq: VCSA), North America's leading vacation rental management platform, released the second edition of its Vacation Rental Search Report today, utilizing 12 months of Vacasa.com data to break down the top guest preferences and booking patterns. Findings in the 2022 Vacation Rental Search Report detail the overarching travel trends shaping how guests search for and secure their stays, as well as which amenities and destinations are proving to be most pop
- Simply Wall St.
Independent Director Karl Peterson Just Bought 46% More Shares In Vacasa, Inc. (NASDAQ:VCSA)
Vacasa, Inc. ( NASDAQ:VCSA ) shareholders (or potential shareholders) will be happy to see that the Independent...
- American City Business Journals
Absci stock gets slammed by macro conditions, rising interest rates
Absci Corp. (Nasdaq: ABSI), a Vancouver, Washington-based synthetic biology company that went public last July, is down 59% so far this year, as the biotech sector as a whole takes a beating. Absci’s stock was trading at $3.42 on Thursday, down from a high of $31.53 on Aug. 4, 2021. The Nasdaq Biotechnology Index is down 27.5% year to date, less than Absci's decline, but still the "worst drawdown" many analysts have seen in 20 years, according to MarketWatch.
